Archives of Clinical Infectious Diseases

Published by: Kowsar

A Surveillance on Protease Inhibitor Resistance-Associated Mutations Among Iranian HIV-1 Patients

Zeynab Nasiri-Tajabadi 1 , Farah Bokharaei Salim 2 , Mohammad-Javad Najafzadeh 3 , 4 , Saeed Kalantari 5 , Saba Garshasbi 6 , Saeid Amel Jamehdar 1 , 7 , Hadi Farsiani 1 , 7 , Zahra Mazaheri 1 , Mojtaba Sankian 8 and Masoud Youssefi 1 , 7 , *
Authors Information
1 Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Virology, Iran University of Medical Sciences, Tehran, Iran
3 Department of Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4 Cancer Molecular Pathology Research Center, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5 Departments of Infectious Diseases and Tropical Medicine, Iran University of Medical Sciences, Tehran, Iran
6 HIV Laboratory of National Center, Deputy of Health, Iran University of Medical Sciences, Tehran, Iran
7 Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
8 Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • Archives of Clinical Infectious Diseases: December 2018, 13 (6); e69153
  • Published Online: September 26, 2018
  • Article Type: Research Article
  • Received: April 7, 2018
  • Revised: July 4, 2018
  • Accepted: July 8, 2018
  • DOI: 10.5812/archcid.69153

To Cite: Nasiri-Tajabadi Z, Bokharaei Salim F, Najafzadeh M, Kalantari S, Garshasbi S , et al. A Surveillance on Protease Inhibitor Resistance-Associated Mutations Among Iranian HIV-1 Patients, Arch Clin Infect Dis. 2018 ; 13(6):e69153. doi: 10.5812/archcid.69153.

Abstract
Copyright © 2018, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Bakhouch K, Oulad-Lahcen A, Bensghir R, Blaghen M, Elfilali KM, Ezzikouri S, et al. The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naive (HIV1)-infected individuals in Casablanca, Morocco. J Infect Dev Ctries. 2009;3(5):380-91. [PubMed: 19759509].
  • 2. Pillay D, Green H, Matthias R, Dunn D, Phillips A, Sabin C, et al. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis. 2005;192(6):967-73. doi: 10.1086/432763. [PubMed: 16107948].
  • 3. Tamalet C, Fantini J, Tourres C, Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: A 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS. 2003;17(16):2383-8. doi: 10.1097/01.aids.0000076341.42412.59. [PubMed: 14571191].
  • 4. DiazGranados CA, Mantilla M, Lenis W. Antiretroviral drug resistance in HIV-infected patients in Colombia. Int J Infect Dis. 2010;14(4):e298-303. doi: 10.1016/j.ijid.2009.05.006. [PubMed: 19665910].
  • 5. Tang MW, Shafer RW. HIV-1 antiretroviral resistance: Scientific principles and clinical applications. Drugs. 2012;72(9):e1-25. doi: 10.2165/11633630-000000000-00000. [PubMed: 22686620]. [PubMed Central: PMC3689909].
  • 6. Vahabpour R, Bokharaei-Salim F, Kalantari S, Garshasbi S, Monavari SH, Esghaei M, et al. HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals. Arch Virol. 2017;162(6):1477-85. doi: 10.1007/s00705-017-3228-1. [PubMed: 28181034].
  • 7. Hirsch MS. HIV drug resistance--a chink in the armor. N Engl J Med. 2002;347(6):438-9. doi: 10.1056/NEJMe020072. [PubMed: 12167687].
  • 8. Shafer RW, Kantor R, Gonzales MJ. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Rev. 2000;2(4):211-28. [PubMed: 19096725]. [PubMed Central: PMC2604813].
  • 9. Dayer MR, Dayer MS. Whiskers-less HIV-protease: A possible way for HIV-1 deactivation. J Biomed Sci. 2013;20:67. doi: 10.1186/1423-0127-20-67. [PubMed: 24024748]. [PubMed Central: PMC3847613].
  • 10. Brik A, Wong CH. HIV-1 protease: Mechanism and drug discovery. Org Biomol Chem. 2003;1(1):5-14. [PubMed: 12929379].
  • 11. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007;21(6):685-92. doi: 10.1097/QAD.0b013e32802ef30c. [PubMed: 17413689].
  • 12. Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: A randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA. 2000;283(4):492-8. [PubMed: 10659875].
  • 13. Eron J Jr, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial. Lancet. 2006;368(9534):476-82. doi: 10.1016/S0140-6736(06)69155-1. [PubMed: 16890834].
  • 14. Mueller SM, Spriewald BM, Bergmann S, Eismann K, Leykauf M, Korn K, et al. Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognition. J Acquir Immune Defic Syndr. 2011;56(2):109-17. doi: 10.1097/QAI.0b013e3181fe946e. [PubMed: 21107269].
  • 15. Rhee SY, Taylor J, Wadhera G, Ben-Hur A, Brutlag DL, Shafer RW. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci U S A. 2006;103(46):17355-60. doi: 10.1073/pnas.0607274103. [PubMed: 17065321]. [PubMed Central: PMC1622926].
  • 16. Nii-Trebi NI, Ibe S, Barnor JS, Ishikawa K, Brandful JA, Ofori SB, et al. HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. PLoS One. 2013;8(8). e71972. doi: 10.1371/journal.pone.0071972. [PubMed: 23977189]. [PubMed Central: PMC3747072].
  • 17. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608-18. doi: 10.1086/503914. [PubMed: 16652319]. [PubMed Central: PMC2547473].
  • 18. Baesi K, Ravanshad M, Ghanbari Safari M, Saberfar E, Hajiabdolbaghi M. [Survey of human immunodeficiency virus-1 protease gene drug resistance among HIV-infected patients in an Iranian research center for HIV/AIDS]. Pathobiol Res. 2012;14(4):13-20. Persian.
  • 19. Hamkar R, Mohraz M, Lorestani S, Aghakhani A, Truong HM, McFarland W, et al. Assessing subtype and drug-resistance-associated mutations among antiretroviral-treated HIV-infected patients. AIDS. 2010;24 Suppl 2:S85-91. doi: 10.1097/01.aids.0000386738.32919.67. [PubMed: 20610954].
  • 20. Naziri H, Tabarraei A, Ghaemi A, Davarpanah MA, Javid N, Moradi A. [Drug- Resistance- Associated Mutations and HIV Sub-Type Determination in Drug-Naive and HIV-Positive Patients under Treatment with Antiretroviral Drugs]. Med Lab J. 2013;7(3):1-8. Persian.
  • 21. Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev. 2012;14(1):17-27. [PubMed: 22297501].
  • 22. Friend J, Parkin N, Liegler T, Martin JN, Deeks SG. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS. 2004;18(14):1965-6. [PubMed: 15353986].
  • 23. Grossman Z, Schapiro JM, Levy I, Elbirt D, Chowers M, Riesenberg K, et al. Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. PLoS One. 2014;9(1). e86239. doi: 10.1371/journal.pone.0086239. [PubMed: 24475093]. [PubMed Central: PMC3903498].
  • 24. Mo H, King MS, King K, Molla A, Brun S, Kempf DJ. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: Mutation patterns and baseline correlates. J Virol. 2005;79(6):3329-38. doi: 10.1128/JVI.79.6.3329-3338.2005. [PubMed: 15731227]. [PubMed Central: PMC1075714].
  • 25. Monno L, Saracino A, Scudeller L, Pastore G, Bonora S, Cargnel A, et al. HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. J Acquir Immune Defic Syndr. 2003;33(4):439-47. [PubMed: 12869832].
  • 26. Luis Jimenez J, Resino S, Martinez-Colom A, Bellon JM, Angeles Munoz-Fernandez M; Spanish Group of Paediatric H.I.V. Infection. Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy. J Antimicrob Chemother. 2005;56(6):1081-6. doi: 10.1093/jac/dki356. [PubMed: 16195257].
  • 27. Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, et al. 2017 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2017;24(4):132-3. [PubMed: 28208121]. [PubMed Central: PMC5677049].
  • 28. Van Marck H, Dierynck I, Kraus G, Hallenberger S, Pattery T, Muyldermans G, et al. Unravelling the complex resistance pathways of darunavir using bioinformatics resistance determination (BIRD). Antivir Ther. 2007;12. S141.
  • 29. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013;21(1):6-14. [PubMed: 23596273].
  • 30. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med. 2008;16(1):62-8. [PubMed: 18441382].
  • 31. Jahanbakhsh F, Hattori J, Matsuda M, Ibe S, Monavari SH, Memarnejadian A, et al. Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011. PLoS One. 2013;8(4). e61864. doi: 10.1371/journal.pone.0061864. [PubMed: 23626742]. [PubMed Central: PMC3633940].
  • 32. Baesi K, Moallemi S, Farrokhi M, Alinaghi SA, Truong HM. Subtype classification of Iranian HIV-1 sequences registered in the HIV databases, 2006-2013. PLoS One. 2014;9(9). e105098. doi: 10.1371/journal.pone.0105098. [PubMed: 25188443]. [PubMed Central: PMC4154867].
  • 33. Soheilli ZS, Ataiee Z, Tootian S, Zadsar M, Amini S, Abadi K, et al. Presence of HIV-1 CRF35_AD in Iran. AIDS Res Hum Retroviruses. 2009;25(1):123-4. doi: 10.1089/aid.2008.0199. [PubMed: 19182925].
  • 34. Baesi K, Moradbeigi M, Ravanshad M, Baghban A. Phylogeny and drug resistance of HIV PR gene among HIV patients receiving RT inhibitors in Iran. Asian Pac J Trop Biomed. 2016;6(5):451-4. doi: 10.1016/j.apjtb.2015.12.020.
  • 35. Gholami M, Sadeghi L, Baesi K, Rouzbahani NH, Mohraz M. Survey of antiretroviral drug resistance pattern among HIV-infected patients with treatment failure in Iran. J Hum Virol Retrovir. 2015;3(1):1-6.
  • 36. Naziri H, Baesi K, Moradi A, Aghasadeghi MR, Tabarraei A, McFarland W, et al. Antiretroviral drug resistance mutations in naive and experienced patients in Shiraz, Iran, 2014. Arch Virol. 2016;161(9):2503-9. doi: 10.1007/s00705-016-2955-z. [PubMed: 27368990].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments